Ambien among sleeping pills that increase risk of hip fracture, study suggests

Share this article:

The class of sleeping medications thought to be safer for nursing home residents than traditional anti-anxiety drugs puts them at a 70% increased risk for hip fracture, a study found.

Following a Medicare Part D change in 2006, physicians started prescribing sleeping pills such as Ambien, Lunesta and Sonata for nursing home residents with insomnia instead of older benzodiazepines, according to researchers from Beth Israel Deaconess Medical Center. The newer sleeping pills were thought to be safer for residents than benzodiazepine hypnotics, researchers noted.

But in a study of 26,618 nursing home residents who had lived in their facilities for at least six months before having a hip fracture, those taking non-benzodiazepine hypnotics had a 70% increased risk for a fracture, MedPage reported. Additionally, the risk was even higher in residents with little or no cognitive impairment compared to those with significant cognitive impairment.

“Restrictive policies on benzodiazepines should be carefully considered," said Sarah Berry, M.D., of Beth Israel Deaconess Medical Center.

The findings were presented over the weekend at the annual meeting of the American Society for Bone and Mineral Research, which was held in Minneapolis.

Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.